Mechanisms of subcutaneous absorption of rituximab in rats

Drug Metabolism and Disposition

Volumn 41, Issue 1, 2013, Pages 248-255

  Kagan, Leonid ^a   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HYALURONIDASE; IMMUNOGLOBULIN G; RITUXIMAB;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SCREENING; LOW DRUG DOSE; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; INFUSIONS, SUBCUTANEOUS; MALE; RATS; RATS, WISTAR;

RATTUS;

EID: 84871563296     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048496     Document Type: Article

References (31)

1. al-Bander HA, Martin VI, and Kaysen GA (1992) Plasma IgG pool is not defended from urinary loss in nephrotic syndrome. Am J Physiol 262:F333-F337.
2. Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, and Wiestner A (2010) Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 95:329-332.
3. Beshyah SA, Anyaoku V, Niththyananthan R, Sharp P, and Johnston DG (1991) The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin Endocrinol (Oxf) 35:409-412.
4. Bittner B and Schmidt J (2012) Subcutaneous administration of monoclonal antibodies in oncology as alternative to established intravenous infusion. Pharm Ind 74:638-643.
5. Bocci V, Muscettola M, Grasso G, Magyar Z, Naldini A, and Szabo G (1986a) The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma. Experientia 42:432-433.
6. Bocci V, Muscettola M, and Naldini A (1986b) The lymphatic route - III. Pharmacokinetics of human natural interferon-beta injected with albumin as a retarder in rabbits. Gen Pharmacol 17:445-448.
7. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, and Frost GI (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114:230-241.
8. Datta-Mannan A, Witcher DR, Lu J, and Wroblewski VJ (2012) Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 4:267-273.
9. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, and Prabhu S (2010) Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:600-605.
10. Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, and Prabhu S (2012) Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs 4:101-109.
11. Frost GI (2007) Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4:427-440.
12. Garg A and Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687-709.
13. Hansen RJ and Balthasar JP (2002) Intravenous immunoglobulin mediates an increase in antiplatelet antibody clearance via the FcRn receptor. Thromb Haemost 88:898-899.
14. Hansen RJ and Balthasar JP (2003) Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92:1206-1215.
15. Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, and Hoffman A (2007) The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm 67:759-765.
16. Kagan L, Turner MR, Balu-Iyer SV, and Mager DE (2012) Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 29:490-499.
17. Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJ, and Charman SA (2007) Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos 35:2211-2217.
18. Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, and Williams JD (1991) Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol 88:152-156, discussion 157-158.
19. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, and Ivens IA (2010) Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther 12:461-470.
20. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, and Dall'acqua WF (2009) Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 46:1750-1755.
21. Pirrello RD, Ting Chen C, and Thomas SH (2007) Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med 10:861-864.
22. Plosker GL and Figgitt DP (2003) Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803-843.
23. Porter CJ and Charman SA (2000) Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89:297-310.
24. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, and Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
25. Richter WF, Bhansali SG, and Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14:559-570.
26. Salauze D, Serre V, and Perrin C (1994) Quantification of total IgM and IgG levels in rat sera by a sandwich ELISA technique. Comp Haematol Int 4:30-33.
27. Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50:3-20.
28. Wang W, Wang EQ, and Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548-558.
29. Xu Z, Wang Q, Zhuang Y, and Frederick BYan HBouman-Thio EMarini JC, Keen M, Snead D, and Davis HM, et al. (2010) Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol 50:276-284.
30. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, and Lowman HB (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182:7663-7671.
31. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, and Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157-159.